share_log

Vivos Therapeutics | CORRESP: CORRESP

SEC ·  Apr 25 00:56
Summary by Futu AI
Vivos Therapeutics, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form S-1, initially filed on April 9, 2024. The company seeks to have the registration become effective at 4:30 p.m. on April 26, 2024. This request was made under Rule 461 of the Securities Act of 1933, as amended. Additionally, Vivos Therapeutics has authorized Lawrence A. Rosenbloom, Esq. of Ellenoff Grossman & Schole LLP to communicate with the SEC staff regarding any potential deferral of the new effective time.
Vivos Therapeutics, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form S-1, initially filed on April 9, 2024. The company seeks to have the registration become effective at 4:30 p.m. on April 26, 2024. This request was made under Rule 461 of the Securities Act of 1933, as amended. Additionally, Vivos Therapeutics has authorized Lawrence A. Rosenbloom, Esq. of Ellenoff Grossman & Schole LLP to communicate with the SEC staff regarding any potential deferral of the new effective time.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.